A compound of formula wherein L is selected from the group consisting of -C - and -CH 2 -; Hy is a monocyclic heteroaryl optionally substituted with one or more groups selected from -(C 1 -C 4)alkyl, halogen atoms, cyano, -(CH 2) n NR 4 R 5, -NH-heterocycloalkyl, -O-(C 1 -C 6)alkyl, -(C 1 -C 6)haloalkyl, -C NH-(C 1 -C 6)alkylene-NR 4 R 5, -O-(C 1 -C 6)alkylene-cycloalkyl, -NHC -(C 1 -C 6)alkyl, -NHC -(C 1 -C 6)alkylene-NR 4 R 5, -NHC -(C 1 -C 6)alkylene-O-(C 1 -C 4)alkyl, -NH-(C 1 -C 6)alkylene-O-(C 1 -C 4)alkyl, -NH-(C 1 -C 6)alkylene-OH, -heteroaryl optionally substituted by one or more -(C 1 -C 4)alkyl, -NH-heteroaryl, wherein said heteroaryl is optionally substituted by one or more -(C 1 -C 4)alkyl, and heterocycloalkyl optionally substituted by one or more groups selected from oxo and -(C 1 -C 6)alkyl; R 1 is selected from the group consisting of: - Het which is an heteroaryl optionally substituted with one or more groups selected from -(C 1 -C 4)alkyl, -(C 1 -C 4)haloalkyl and aryl, wherein said aryl is optionally substituted with one or more groups selected from -(C 1 -C 4)alkyl and halogen atoms; and - X wherein R 2 is selected from the group consisting of -O(C 1 -C 4)haloalkyl, halogen atoms, - O(C 3 -C 7)cycloalkyl and -(C 1 -C 4)haloalkyl; R 3 is H or is selected from the group consisting of halogen atoms, cyano, -O(C 1 -C 4)alkyl, -O(C 1 -C 4)haloalkyl, heterocycloalkyl-(C 1 -C 4)alkylene-, -(C 1 -C 4)alkylene-heterocycloalkyl-NR 4 R 5, and heteroaryl optionally substituted with one or more -(C 1 -C 4)alkyl, and wherein said heterocycloalkyl is optionally substituted with one or more -(C 1 -C 4)alkyl; n is 0, 1 or 2; R 4 is H or -(C 1 -C 4)alkyl; R 5 is H or -(C 1 -C 4)alkyl; and pharmaceutically acceptable salts thereof. L is selected from the group consisting of -C - and -CH 2 -; Hy is a monocyclic heteroaryl optionally substituted with one or more groups selected from -(C 1 -C 4)alkyl, halogen atoms, cyano, -(CH 2) n NR 4 R 5, -NH-heterocycloalkyl, -O-(C 1 -C 6)alkyl, -(C 1 -C 6)haloalkyl, -C NH-(C 1 -C 6)alkylene-NR 4 R 5, -O-(C 1 -C 6)alkylene-cycloalkyl, -NHC -(C 1 -C 6)alkyl, -NHC -(C 1 -C 6)alkylene-NR 4 R 5, -NHC -(C 1 -C 6)alkylene-O-(C 1 -C 4)alkyl, -NH-(C 1 -C 6)alkylene-O-(C 1 -C 4)alkyl, -NH-(C 1 -C 6)alkylene-OH, -heteroaryl optionally substituted by one or more -(C 1 -C 4)alkyl, -NH-heteroaryl, wherein said heteroaryl is optionally substituted by one or more -(C 1 -C 4)alkyl, and heterocycloalkyl optionally substituted by one or more groups selected from oxo and -(C 1 -C 6)alkyl; R 1 is selected from the group consisting of: - Het which is an heteroaryl optionally substituted with one or more groups selected from -(C 1 -C 4)alkyl, -(C 1 -C 4)haloalkyl and aryl, wherein said aryl is optionally substituted with one or more groups selected from -(C 1 -C 4)alkyl and halogen atoms; and - X wherein R 2 is selected from the group consisting of -O(C 1 -C 4)haloalkyl, halogen atoms, - O(C 3 -C 7)cycloalkyl and -(C 1 -C 4)haloalkyl; R 3 is H or is selected from the group consisting of halogen atoms, cyano, -O(C 1 -C 4)alkyl, -O(C 1 -C 4)haloalkyl, heterocycloalkyl-(C 1 -C 4)alkylene-, -(C 1 -C 4)alkylene-heterocycloalkyl-NR 4 R 5, and heteroaryl optionally substituted with one or more -(C 1 -C 4)alkyl, and wherein said heterocycloalkyl is optionally substituted with one or more -(C 1 -C 4)alkyl; n is 0, 1 or 2; R 4 is H or -(C 1 -C 4)alkyl; R 5 is H or -(C 1 -C 4)alkyl; and pharmaceutically acceptable salts thereof. - Het which is an heteroaryl optionally substituted with one or more groups selected from -(C 1 -C 4)alkyl, -(C 1 -C 4)haloalkyl and aryl, wherein said aryl is optionally substituted with one or more groups selected from -(C 1 -C 4)alkyl and halogen atoms; and - X wherein R 2 is selected from the group consisting of -O(C 1 -C 4)haloalkyl, halogen atoms, - O(C 3 -C 7)cycloalkyl and -(C 1 -C 4)haloalkyl; R 3 is H or is selected from the group consisting of halogen atoms, cyano, -O(C 1 -C 4)alkyl, -O(C 1 -C 4)haloalkyl, heterocycloalkyl-(C 1 -C 4)alkylene-, -(C 1 -C 4)alkylene-heterocycloalkyl-NR 4 R 5, and heteroaryl optionally substituted with one or more -(C 1 -C 4)alkyl, and wherein said heterocycloalkyl is optionally substituted with one or more -(C 1 -C 4)alkyl; n is 0, 1 or 2; R 4 is H or -(C 1 -C 4)alkyl; R 5 is H or -(C 1 -C 4)alkyl; and pharmaceutically acceptable salts thereof. R 2 is selected from the group consisting of -O(C 1 -C 4)haloalkyl, halogen atoms, - O(C 3 -C 7)cycloalkyl and -(C 1 -C 4)haloalkyl; R 3 is H or is selected from the group consisting of halogen atoms, cyano, -O(C 1 -C 4)alkyl, -O(C 1 -C 4)haloalkyl, heterocycloalkyl-(C 1 -C 4)alkylene-, -(C 1 -C 4)alkylene-heterocycloalkyl-NR 4 R 5, and heteroaryl optionally substituted with one or more -(C 1 -C 4)alkyl, and wherein said heterocycloalkyl is optionally substituted with one or more -(C 1 -C 4)alkyl; n is 0, 1 or 2; R 4 is H or -(C 1 -C 4)alkyl; R 5 is H or -(C 1 -C 4)alkyl; and pharmaceutically acceptable salts thereof.